Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001756445 | SCV001985208 | uncertain significance | not provided | 2023-04-03 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; Although located in a calcium-binding EGF-like domain of the FBN2 gene, it does not substitute or introduce a cysteine residue (Callewaert et al., 2009; Frederic et al., 2009) |
Labcorp Genetics |
RCV002032763 | SCV002270340 | benign | Congenital contractural arachnodactyly | 2023-08-04 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003298960 | SCV003997582 | uncertain significance | Familial thoracic aortic aneurysm and aortic dissection | 2023-05-19 | criteria provided, single submitter | clinical testing | The p.P1429L variant (also known as c.4286C>T), located in coding exon 33 of the FBN2 gene, results from a C to T substitution at nucleotide position 4286. The proline at codon 1429 is replaced by leucine, an amino acid with similar properties. This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |